Atara Biotherapeutics upgraded to Outperform from Neutral at Mizuho
PremiumThe FlyAtara Biotherapeutics upgraded to Outperform from Neutral at Mizuho
1M ago
Atara Biotherapeutics Announces CEO Transition and New Leadership Compensation
Premium
Company Announcements
Atara Biotherapeutics Announces CEO Transition and New Leadership Compensation
1M ago
Atara sees FY24 OpEx down roughly 35% year-over-year
Premium
The Fly
Atara sees FY24 OpEx down roughly 35% year-over-year
1M ago
Atara Biotherapeutics trading halted, news pending
PremiumThe FlyAtara Biotherapeutics trading halted, news pending
3M ago
Atara Biotherapeutics announces 1-for-25 reverse stock split
Premium
The Fly
Atara Biotherapeutics announces 1-for-25 reverse stock split
3M ago
Atara Biotherapeutics presents preclinical ATA3219 data at ISCT 2024
Premium
The Fly
Atara Biotherapeutics presents preclinical ATA3219 data at ISCT 2024
4M ago
Atara Biotherapeutics Board Member Decides Not to Seek Re-Election
PremiumCompany AnnouncementsAtara Biotherapeutics Board Member Decides Not to Seek Re-Election
6M ago
Atara Biotherapeutics’ Profitability Hinges on Partners’ Success with Ebvallo Amid Market Challenges
Premium
Company Announcements
Atara Biotherapeutics’ Profitability Hinges on Partners’ Success with Ebvallo Amid Market Challenges
6M ago
FDA clears Atara’s IND application in LN for allogeneic CAR T therapy ATA3219
Premium
The Fly
FDA clears Atara’s IND application in LN for allogeneic CAR T therapy ATA3219
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100